Posted by Michael Wonder on 02 Jan 2023
China CDE/NMPA recommends priority review for Nefecon for the treatment of primary IgA nephropathy
30 December 2022 - Calliditas Therapeutics' partner Everest Medicines today announced that the Center for Drug Evaluation of the China NMPA has recommended priority review for the new drug application of Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression.
In November 2022 the NMPA accepted Everest's new drug application for Nefecon, leading to an expected regulatory decision in 2H 2023.
